LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

Authors:
  • JKJ.E. Kurtz
    J.E. Kurtz
  • EPE. Pujade-Lauraine
    E. Pujade-Lauraine
  • AOA. Oaknin
    A. Oaknin
  • LBL. Belin
    L. Belin
  • ITI. Tsibulak
    I. Tsibulak
  • DCD. Cibula
    D. Cibula
  • IVI.B. Vergote
    I.B. Vergote
  • ORO.S. Rosengarten
    O.S. Rosengarten
  • MRM.J. Rodrigues
    M.J. Rodrigues
  • NGN. de Gregorio
    N. de Gregorio
  • JMJ. Martinez-Garcia
    J. Martinez-Garcia
  • PPP. Pautier
    P. Pautier

Abstract
No abstract available